Tetrindole

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Tom.Reding (talk | contribs) at 14:07, 12 June 2016 (Fix Category:Pages using citations with accessdate and no URL when perm identifier present (doi|bibcode|arxiv|pmid|jstor|isbn|issn|lccn|oclc|ismn|hdl) (rem access-date) using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Tetrindole
Clinical data
ATC code
  • None
Identifiers
  • 2,3,3a,4,5,6-Hexahydro-8-cyclohexyl-1H-pyrazino[3,2,1-j,k]carbazole
PubChem CID
ChemSpider
ChEBI
Chemical and physical data
FormulaC20H26N2
Molar mass294.43 g/mol g·mol−1
3D model (JSmol)
  • C1CCC(CC1)C2=CC3=C(C=C2)N4CCNC5C4=C3CCC5
  • InChI=1S/C20H26N2/c1-2-5-14(6-3-1)15-9-10-19-17(13-15)16-7-4-8-18-20(16)22(19)12-11-21-18/h9-10,13-14,18,21H,1-8,11-12H2 checkY
  • Key:AUXCHYJDVJZEPG-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Tetrindole was a drug candidate that functions by reversibly inhibiting monoamine oxidase A; it was first synthesized in Moscow in the early 1990s.[1] Tetrindole is similar in its chemical structure to pirlindole (Pyrazidol), and metralindole.[2]

References

  1. ^ Medvedev, AE; Kirkel, AA; Kamyshanskaya, NS; Moskvitina, TA; Axenova, LN; Gorkin, VZ; Andreeva, NI; Golovina, SM; Mashkovsky, MD (20 January 1994). "Monoamine Oxidase Inhibition by Novel Antidepressant Tetrindole". Biochemical Pharmacology. 47 (2): 303–8. doi:10.1016/0006-2952(94)90021-3. PMID 8304974.
  2. ^ Ramsay, RR; Gravestock, MB (March 2003). "Monoamine Oxidases: to Inhibit or Not to Inhibit". Mini Reviews in Medicinal Chemistry. 3 (2): 129–36. doi:10.2174/1389557033405287. PMID 12570845.